Quit/Reduce Smoking
Improves Health
Season 3 Episode 40
| Brand | Smotect |
| Company Name | PAYU PAYMENTS PRIVATE LIMITED |
| Founders | Gurseet Singh |
| Original Ask | 1 crore for 1% equity at the valuation of Rs. 100 crores |
| Deal | 50 lakhs for 5% equity at the valuation of Rs. 10 crores and 50 lakhs debt at 15% interest for 3 years |
About the Product
Smotect’s polyherbal natural formula stands as the world’s pioneering nicotine-free and natural solution tailored for tobacco users. Scientifically validated, it readies the body and mind to break free from tobacco addiction by diminishing dependence on nicotine. This innovative formula not only aids in quitting tobacco but also shields and rejuvenates vital organs such as the lungs, heart, brain, skin, and the oral cavity from the long-term effects of tobacco usage.
Adhering to international quality standards, Smotect maintains an unwavering commitment to delivering consistent and standardized products across all productions. With zero variations and a steadfast dedication to 100% quality, their offerings are FDA approved, nicotine-free, and backed by patented formulas. Additionally, Smotect’s products hold GMP certification and are clinically proven to ensure efficacy and safety.
Among their standout products is the Smotect Natural Tablets to Quit Smoking, uniquely formulated to aid in smoking cessation. These tablets are nicotine-free and boast zero side effects, making them a safe and effective option for those looking to quit smoking. Derived from 12 therapeutic herbs, these tablets are FDA approved, GMP certified, and patented, underscoring Smotect’s commitment to providing high-quality solutions for tobacco cessation.
Founders & their story
- Gurseet Singh
Smotect offers 100% natural, nicotine-free tablets designed to assist individuals in quitting smoking while simultaneously repairing the damage caused by smoking. Their formulation is deemed both safe and effective, having surpassed the gold standard for clinical trials. With a customer base of 20,000 paid users, Smotect boasts a remarkable success rate of 95% as observed in a double-blinded, randomized, placebo-controlled multicentric study. Their journey began in 2014 with research and development efforts, leading to the initiation of clinical trials in 2016. These trials, conducted on 100 patients, underscore the efficacy of Smotect’s tablets in aiding smoking cessation and promoting overall health. The prescribed consumption of these tablets is four per day, with a price point set at 3000.
Currently serving a customer base of 40,000 individuals, Smotect attracts an impressive monthly influx of new customers ranging from 3,500 to 4,000. On average, customers utilize Smotect’s tablets for a duration of 1.5 to 2 months, contributing to their success in achieving smoking cessation goals. Driven by a founder’s investment of 5-6 crores, Smotect operates with a dedicated team of 10 individuals, working tirelessly to support individuals on their journey to a smoke-free life and better health.
About the company
Smotect stands as a leading wellness company committed to empowering individuals to embrace a tobacco-free lifestyle and thrive through holistic wellness solutions. Their dedication extends to eradicating tobacco from society, striving to foster a healthier and happier world. With over eight years of focused research and development, the company has assembled a team of experts, including doctors, scientists, and psychologists, to innovate solutions for quitting tobacco.
Since 2015, Smotect has conducted numerous clinical trials and extensive research, aiding many individuals in overcoming their smoking habits, with over 40,000 success stories to date. Their vision is to positively impact society by catalyzing transformation towards an improved quality of life for all, while their mission centers on assisting tobacco users by offering scientific support and guidance throughout their quitting journey. Smotect’s holistic approach to wellness underscores their commitment to helping individuals break free from tobacco addiction and achieve lasting health and well-being.
Revenue
In September 2023, Smotect recorded sales amounting to 1 crore. Projected sales for the fiscal year 2023-2024 stand at an impressive 12 crores. As of September in the fiscal year 2023-2024, the profit after tax stands at 12%, with a notable gross margin of 80%.
Founders’ Ask
1 crore for 1% equity at the valuation of Rs. 100 crores.
Offers
Anupam’s offer: 50 lakhs for 5% equity at the valuation of Rs. 10 crores and 50 lakhs debt at 15% interest for 3 years.
Conditions Being:
- Efficacy claims and studies have to be verified.
- Product offering will be expanded to include Ayurvedic products that are not related to quitting smoking.
Founder’s Counteroffer
Offer 1: 50 lakhs for 2% equity at the valuation of Rs. 25 crores and 50 lakhs debt at 15% interest for 3 years.
Offer 1: 50 lakhs for 3% equity at the valuation of Rs. 16.67 crores and 50 lakhs debt at 15% interest for 3 years.
Final Deal
Anupam: 50 lakhs for 5% equity at the valuation of Rs. 10 crores and 50 lakhs debt at 15% interest for 3 years.
